Comparative Pharmacology
Head-to-head clinical analysis: KLOXXADO versus NALOXONE HCL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KLOXXADO versus NALOXONE HCL.
KLOXXADO vs NALOXONE HCL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
KLOXXADO (flumazenil) is a benzodiazepine antagonist that competitively inhibits the activity at the benzodiazepine binding site on the GABA-A receptor, thereby reversing the effects of benzodiazepines.
Competitive antagonist at mu, kappa, and delta opioid receptors, reversing opioid-induced respiratory depression and analgesia.
5 mg intranasally as a single dose; may repeat once after 2-3 minutes if response inadequate.
0.4 mg to 2 mg IV, IM, or subcutaneously, may repeat every 2-3 minutes as needed. For continuous infusion, IV infusion rate of 0.25-6.25 mg/hour.
None Documented
None Documented
Terminal elimination half-life is approximately 2 hours (range 1-4 hours); clinical context: short half-life supports rapid reversal of opioid effects but requires monitoring for renarcotization, especially with long-acting opioids.
Terminal elimination half-life is 1.0-1.5 hours in adults. In neonates, half-life is prolonged (3-4 hours) due to immature hepatic function. Clinically, the short half-life necessitates repeated or continuous dosing to reverse opioid effects lasting longer than naloxone's duration.
Hepatic metabolism primarily via CYP3A4 to inactive metabolites; renal excretion accounts for <1% of unchanged drug; fecal excretion accounts for approximately 50-60% of the dose as metabolites.
Primarily hepatic metabolism (glucuronidation). Renal excretion accounts for approximately 50% of total clearance, with biliary/fecal elimination contributing 20-30%. Unchanged naloxone in urine is <5%.
Category C
Category A/B
Opioid Antagonist
Opioid Antagonist